Vanderbilt-Ingram Cancer Center
-
November 2, 2021
Shifts in neuroendocrine cancer clinical trial design
Clinical trials that focus on specific types of neuroendocrine neoplasms — heterogeneous tumors that can occur anywhere in the body — will be more likely to enhance drug development for these tumors, Vanderbilt physicians assert. -
October 28, 2021
VICC’s Mayer departing to take new role with AstraZeneca
Ingrid Mayer, MD, MSCI, is departing Vanderbilt University Medical Center for a new role as an executive with AstraZeneca. -
October 21, 2021
Study to evaluate how environment impacts cancer risk
Vanderbilt-Ingram Cancer Center is leading an ambitious project to assess the impact of environmental exposures on cancer risk for people living in Southern states. -
October 14, 2021
Photoimmunotherapy offered in clinical trial for recurrent head and neck cancer
Vanderbilt-Ingram Cancer Center is recruiting patients for a clinical trial using photoimmunotherapy for recurrent head and neck cancer. -
September 30, 2021
Study shows how a protein coding gene confers breast cancer susceptibility during DNA transcription
Vanderbilt-Ingram Cancer Center research is providing new insights into how genetic variants convey breast cancer susceptibility by altering the transcription factor proteins that convert DNA strands into RNA. -
September 23, 2021
Clinical trial tests ATR inhibitor in difficult-to-treat cancers
-
September 23, 2021
Eng named co-chair of NCI clinical trials steering committee
Vanderbilt's Cathy Eng, MD, has been elected co-chair of the National Cancer Institute (NCI) Gastrointestinal Cancer Steering Committee.